首页> 外文期刊>World Journal of Urology >Oncologic outcome of 132 cases of laparoscopic radical nephrectomy with intact specimen removal for T1-2N0M0 renal cell carcinoma
【24h】

Oncologic outcome of 132 cases of laparoscopic radical nephrectomy with intact specimen removal for T1-2N0M0 renal cell carcinoma

机译:132例T1-2N0M0肾细胞癌腹腔镜根治性肾切除术完整标本切除术的肿瘤学结局

获取原文
获取原文并翻译 | 示例
           

摘要

We present the short and long-term oncologic outcome of 132 patients with pathologically confirmed T1–T2, N0M0 renal cell carcinoma (RCC), who underwent laparoscopic radical nephrectomy with intact specimen removal at our institution. Beginning January 1998, we prospectively collected data of 132 patients undergoing laparoscopic radical nephrectomy, whose final pathologic stage was T1 or T2, N0M0, RCC. The clinical data of three groups categorized as group (pT1a)—36 patients, group (pT1b)—51 patients and group (pT2)—45 patients were analyzed statistically to assess oncological outcome. The specimens were removed intact without morcellation in all patients in a homemade plastic bag. The total median follow-up was 56 months (range 3–80 months) and there were no local or port-site recurrences or hernia. Patients with pT2 tumors had significantly greater operating time, blood loss and analgesic requirements than pT1a/pT1b tumor patients. The distant metastases were found in 1, 4 and 5 patients in group pT1a, pT1b and pT2, respectively. The 5-year cancer-specific survival was 97.2, 86.3 and 82.2%, respectively, in pT1a, pT1b and pT2 tumor patients (significantly lower in pT2 than pT1a, P = 0.008). The 5-year recurrence-free survival was 97.2, 84.3 and 82.2%, respectively, in pT1a, pT1b and pT2 tumor patients (significantly lower in pT2 than pT1a, P = 0.02). Laparoscopic radical nephrectomy (retroperitoneal and transperitoneal route) with intact specimen removal for localized renal cell carcinoma (T1-2N0M0) provides satisfactory short and long-term oncologic efficacy.
机译:我们介绍了132例经病理证实的T1-T2,N0M0肾细胞癌(RCC)的短期和长期肿瘤学结局,这些患者在我们机构接受了腹腔镜根治性肾切除术并完整取出了标本。从1998年1月开始,我们前瞻性收集了132例接受腹腔镜根治性肾切除术的患者的数据,其最终病理分期为T1或T2,N0M0,RCC。对三组(pT1a)-36例,组(pT1b)-51例和组(pT2)-45例的三组患者的临床数据进行统计学分析,以评估其肿瘤学结局。所有患者均用自制塑料袋完整无损地取出标本。总的中位随访时间为56个月(范围3–80个月),没有局部或港口复发或疝气。与pT1a / pT1b肿瘤患者相比,pT2肿瘤患者的手术时间,失血量和镇痛要求明显更高。 pT1a,pT1b和pT2组分别在1、4和5位患者中发现远处转移。 pT1a,pT1b和pT2肿瘤患者的5年癌症特异性生存率分别为97.2%,86.3%和82.2%(pT2中的显着性低于pT1a,P = 0.008)。 pT1a,pT1b和pT2肿瘤患者的5年无复发生存率分别为97.2%,84.3%和82.2%(pT2明显低于pT1a,P = 0.02)。腹腔镜根治性肾切除术(腹膜后和腹膜途径)可完整切除局部肾细胞癌(T1-2N0M0),具有令人满意的短期和长期肿瘤学疗效。

著录项

  • 来源
    《World Journal of Urology》 |2007年第6期|619-626|共8页
  • 作者单位

    Department of Urology All India Institute of Medical Sciences New Delhi 110029 India;

    Department of Urology All India Institute of Medical Sciences New Delhi 110029 India;

    Department of Urology All India Institute of Medical Sciences New Delhi 110029 India;

    Department of Urology All India Institute of Medical Sciences New Delhi 110029 India;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    Kidney; Carcinoma; Laparoscopy; Nephrectomy;

    机译:肾脏;癌;腹腔镜;肾切除术;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号